HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Natural Products Group files Chapter 11

This article was originally published in The Rose Sheet

Executive Summary

Parent company of Nature's Gate personal-care products and skin-care direct seller Arbonne International filed for Chapter 11 bankruptcy Jan. 27 in the U.S. Bankruptcy Court of Wilmington, Del. Natural Products Group announced a "pre-packaged" restructuring plan that will allow the firm to emerge from bankruptcy in approximately 60 days, as well as reduce its debt obligations by more than 80% and "enhance the company's financial position." The process will not have an impact on day-to-day operations of the firm and its subsidiaries, it says. Annual revenue for the Irvine, Calif.-based private firm totals $451 mil., including $378 mil. from Arbonne and $73 mil. from Levlad Inc., which owns Nature's Gate

You may also be interested in...



Serum Institute-Novavax Seal Win-Win Deal For COVID-19 Vaccine

Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in a few regions. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India till deal ends and non-exclusive rights for developing countries till pandemic lasts, with Novavax getting half of net revenue.

Infographic: Heart Failure Market Set To Reach Almost $12.5Bn In 2022

The market for heart failure diagnostics and devices is set to grow by 3.8% annually in the next three years, with emerging markets leading the growth, according to the new Meddevicetracker Dashboard.

Rosemont Deal Shows Value Is Out There For US Exit, Perrigo Says

Perrigo management provided colorful commentary on Perrigo’s latest endeavors to separate the company’s US generics business, following the recent sale of Perrigo’s Rosemont Pharmaceuticals subsidiary for an “attractive” multiple.

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel